Department of Pathology, Theodor Bilharz Research Institute, Giza, Egypt.
Faculty of Biotechnology, October University of Modern Science and Arts, Giza, Egypt.
Asian Pac J Cancer Prev. 2024 Oct 1;25(10):3691-3699. doi: 10.31557/APJCP.2024.25.10.3691.
Colorectal cancer is the 4th most reported reason for cancer death worldwide. It is a complex and multifaceted disease with diverse histopathological manifestations. CD70 is present on activated immune cells and is upregulated in patients who have finished adjuvant therapy. VEGF controls angiogenesis and demonstrates immuno-regulatory characteristics that inhibit the anticancer activity of immune cells. CD90 is an extracellular cancer stem cell marker and regulates apoptosis, cell migration, and T cell activation.
to elucidate the prognostic potential of a combined immunohistochemical assessment of CD70, VEGF, and CD90 biomarkers in colorectal cancer tissues.
Our study is a retrospective study done on 70 paraffin blocks (45 colorectal carcinoma cases and 11 adenomas, along with 14 cases of colitis serving as controls) were subjected to conventional Hematoxylin and Eosin stain for routine histopathological assessment and immunohistochemical staining for CD70, VEGF and CD90. Our investigation focused on evaluating the expression of CD70, VEGF, and CD90 in various colorectal tissues, including colitis, adenomas, and adenocarcinomas, as well as different grades of adenocarcinoma tissues, different stages of tumor invasiveness, and lymph node status.
Our research revealed distinctive expression patterns of CD70, VEGF, and CD90 across different stages and grades of colorectal cancer.
our research signifies the potential clinical utility of the CD70, VEGF, and CD90 triad as prognostic markers in colorectal cancer. The combined analysis of these markers emerged as a potent prognostic tool, offering valuable insights into disease progression. Our research showed that epithelial CD90 is the most sensitive marker for both tumor stage and lymph node status. CD70 and VEGF showed a statistically significant relation with lymph node status only and not with tumor stage.
结直肠癌是全球第四大常见癌症死因。它是一种复杂且多方面的疾病，具有多种组织病理学表现。CD70 存在于活化的免疫细胞上，并在上接受辅助治疗的患者中上调。VEGF 控制血管生成，并表现出免疫调节特征，抑制免疫细胞的抗癌活性。CD90 是细胞外癌症干细胞标志物，调节细胞凋亡、细胞迁移和 T 细胞激活。
阐明 CD70、VEGF 和 CD90 生物标志物联合免疫组织化学评估在结直肠癌组织中的预后潜力。
我们的研究是一项回顾性研究，对 70 个石蜡块（45 例结直肠癌病例和 11 例腺瘤，以及 14 例结肠炎作为对照）进行了常规苏木精和伊红染色的常规组织病理学评估和 CD70、VEGF 和 CD90 的免疫组织化学染色。我们的研究重点评估了 CD70、VEGF 和 CD90 在不同的结直肠组织中的表达，包括结肠炎、腺瘤和腺癌，以及不同等级的腺癌组织、不同阶段的肿瘤侵袭性和淋巴结状态。
我们的研究揭示了 CD70、VEGF 和 CD90 在不同阶段和等级的结直肠癌中的独特表达模式。
我们的研究表明，CD70、VEGF 和 CD90 三联体作为结直肠癌的预后标志物具有潜在的临床应用价值。这些标志物的联合分析成为一种强大的预后工具，提供了对疾病进展的有价值的见解。我们的研究表明，上皮 CD90 是最敏感的肿瘤分期和淋巴结状态标志物。CD70 和 VEGF 仅与淋巴结状态具有统计学显著关系，而与肿瘤分期无关。
